{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:00:21Z","timestamp":1791172821552,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006239","name":"Society of Nuclear Medicine and Molecular Imaging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000945","name":"Pittsburgh Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijrobp.2025.09.028","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T22:21:47Z","timestamp":1758579707000},"page":"575-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2121-2993","authenticated-orcid":false,"given":"Jackson N.","family":"Howell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole M.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Barney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy E.","family":"Escorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Boothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.09.028_bib0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2022.08.010","article-title":"A primer on radiopharmaceutical therapy","volume":"115","author":"Salerno","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0002","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2967\/jnumed.118.214122","article-title":"The current state of radiopharmaceutical therapy","volume":"59","author":"Divgi","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0003","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijrobp.2020.08.035","article-title":"Current status of radiopharmaceutical therapy","volume":"109","author":"St James","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0005","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0007","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2020.09.029","article-title":"US radiation oncologists (re)defined: An American Society for Radiation Oncology scope of practice study","volume":"109","author":"Fung","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0008","article-title":"Unsealed source: Scope of practice for radiopharmaceuticals among United States radiation oncologists","volume":"7","author":"Shukla","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0009","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-022-05785-x","article-title":"Joint EANM, SNMMI and IAEA enabling guide: How to set up a theranostics centre","volume":"49","author":"Herrmann","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.brachy.2020.07.004","article-title":"Initial experience and lessons learned with implementing lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology-based program","volume":"20","author":"Maughan","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0011","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0012","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2022.03.018","article-title":"ASTRO\u2019s framework for radiopharmaceutical therapy curriculum development for trainees","volume":"113","author":"Kiess","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ijrobp.2020.11.048","article-title":"A framework for patient-centered pathways of care for radiopharmaceutical therapy: An ASTRO consensus document","volume":"109","author":"Buatti","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0014","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.prro.2025.03.006","article-title":"Quality and safety considerations for radiopharmaceutical therapy in the radiation oncology environment: An ASTRO safety white paper","volume":"15","author":"Zoberi","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2967\/jnumed.120.258103","article-title":"Landscape analysis of phase 2 and 3 clinical trials for targeted radionuclide therapy","volume":"62","author":"Mittra","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.028_bib0016","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: A review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162506290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162506290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:58:45Z","timestamp":1773205125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162506290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S036030162506290X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.028","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}